Compare · BIS vs HCXY
BIS vs HCXY
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.43B.
- HCXY has hit the wire 4 times in the past 4 weeks while BIS has been quiet.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIS
Latest HCXY
- Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
- Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call
- Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029
- Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029
- Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
- Hercules Capital’s Investment Adviser Surpasses $2.3 Billion in Investable Capital
- Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031